ES2531846T3 - Composición farmacéutica tópica de mupirocina - Google Patents
Composición farmacéutica tópica de mupirocina Download PDFInfo
- Publication number
- ES2531846T3 ES2531846T3 ES11770791.9T ES11770791T ES2531846T3 ES 2531846 T3 ES2531846 T3 ES 2531846T3 ES 11770791 T ES11770791 T ES 11770791T ES 2531846 T3 ES2531846 T3 ES 2531846T3
- Authority
- ES
- Spain
- Prior art keywords
- mupirocin
- pharmaceutical
- composition
- composition according
- veterinary composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical group O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 title claims abstract description 103
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 title claims abstract description 102
- 229960003128 mupirocin Drugs 0.000 title claims abstract description 88
- 229930187697 mupirocin Natural products 0.000 title claims abstract description 88
- 239000012049 topical pharmaceutical composition Substances 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 120
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229940057917 medium chain triglycerides Drugs 0.000 claims abstract description 34
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 29
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 29
- 239000000227 bioadhesive Substances 0.000 claims abstract description 22
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 18
- 239000002904 solvent Substances 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004264 Petrolatum Substances 0.000 claims abstract description 9
- 229940066842 petrolatum Drugs 0.000 claims abstract description 9
- 235000019271 petrolatum Nutrition 0.000 claims abstract description 9
- 229920000193 polymethacrylate Polymers 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940074928 isopropyl myristate Drugs 0.000 claims abstract description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940042129 topical gel Drugs 0.000 claims abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000006172 buffering agent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 24
- 230000000699 topical effect Effects 0.000 description 22
- 229920003082 Povidone K 90 Polymers 0.000 description 18
- 238000009472 formulation Methods 0.000 description 16
- 229940028420 bactroban Drugs 0.000 description 13
- 238000011282 treatment Methods 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 235000019445 benzyl alcohol Nutrition 0.000 description 8
- 229960004217 benzyl alcohol Drugs 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000002674 ointment Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- MINDHVHHQZYEEK-HBBNESRFSA-N mupirocin Chemical compound C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-HBBNESRFSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 229920003136 Eudragit® L polymer Polymers 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- VFPFQHQNJCMNBZ-UHFFFAOYSA-N ethyl gallate Chemical compound CCOC(=O)C1=CC(O)=C(O)C(O)=C1 VFPFQHQNJCMNBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 235000001942 Elaeis Nutrition 0.000 description 1
- 241000512897 Elaeis Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000004262 Ethyl gallate Substances 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 235000019277 ethyl gallate Nutrition 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N gallic acid propyl ester Natural products CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 229940100657 nasal ointment Drugs 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000013148 permeation assay Methods 0.000 description 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000019585 progressive encephalomyelitis with rigidity and myoclonus Diseases 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical class [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382274 | 2010-10-20 | ||
| EP10382274A EP2444067A1 (en) | 2010-10-20 | 2010-10-20 | Anhydrous gel comprising mupirocin |
| PCT/EP2011/068242 WO2012052472A1 (en) | 2010-10-20 | 2011-10-19 | Pharmaceutical topical composition of mupirocin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2531846T3 true ES2531846T3 (es) | 2015-03-20 |
Family
ID=44050874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11770791.9T Active ES2531846T3 (es) | 2010-10-20 | 2011-10-19 | Composición farmacéutica tópica de mupirocina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9205149B2 (enExample) |
| EP (2) | EP2444067A1 (enExample) |
| JP (1) | JP5954745B2 (enExample) |
| KR (1) | KR101776362B1 (enExample) |
| CN (1) | CN103189048B (enExample) |
| AU (1) | AU2011317636B2 (enExample) |
| BR (1) | BR112013009371B1 (enExample) |
| CA (1) | CA2814103C (enExample) |
| ES (1) | ES2531846T3 (enExample) |
| MX (1) | MX2013004394A (enExample) |
| NZ (1) | NZ609655A (enExample) |
| PL (1) | PL2629756T3 (enExample) |
| PT (1) | PT2629756E (enExample) |
| RU (1) | RU2563840C2 (enExample) |
| WO (1) | WO2012052472A1 (enExample) |
| ZA (1) | ZA201302560B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150027831A (ko) * | 2012-07-06 | 2015-03-12 | 레오 파마 에이/에스 | 피부에 활성 성분을 전달하기 위한 막-형성 중합체를 포함하는 국소 조성물 |
| EP2742932A1 (en) | 2012-12-17 | 2014-06-18 | Laboratorios Ojer Pharma S.L. | Gel compositions |
| WO2016133471A1 (en) | 2015-02-20 | 2016-08-25 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A. Ş. | A topical composition comprising mupirocin and dexpanthenol |
| EP3346998B1 (en) | 2015-08-17 | 2025-04-16 | Sidmak Laboratories (India) PVT. Ltd. | Topical film delivery system |
| KR101717699B1 (ko) | 2016-02-11 | 2017-03-17 | 아이큐어 주식회사 | 카타플라스마제용 자외선 경화형 하이드로젤 수지, 하이드로젤 및 이를 포함하는 카타플라스마제 |
| WO2020141482A1 (en) * | 2019-01-04 | 2020-07-09 | Glenmark Specialty S.A. | Pharmaceutical compositions comprising mupirocin |
| CN110090198B (zh) * | 2019-05-09 | 2020-02-21 | 哈尔滨乾佰纳生物药业有限公司 | 一种具有生物粘附性的缓释型口腔溃疡凝胶及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8530796D0 (en) * | 1985-12-13 | 1986-01-22 | Beecham Group Plc | Pharmaceutical composition |
| IE59628B1 (en) | 1986-06-26 | 1994-03-09 | Beecham Group Plc | Treatment of fungal infections |
| GB8615669D0 (en) * | 1986-06-26 | 1986-07-30 | Beecham Group Plc | Treatment |
| GB9321876D0 (en) * | 1993-10-22 | 1993-12-15 | Smithkline Beecham Corp | Novel composition |
| AUPO379596A0 (en) | 1996-11-22 | 1996-12-19 | Soltec Research Pty Ltd | Percutaneous delivery system |
| WO1999012520A1 (en) * | 1997-09-11 | 1999-03-18 | Smithkline Beecham Plc | Compositions adapted for prolonged residence in the nasal pharynx |
| IL137363A (en) | 2000-07-18 | 2005-12-18 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing mupirocin |
| AU2002950506A0 (en) * | 2002-07-31 | 2002-09-12 | Soltec Research Pty Ltd | Percutaneous delivery system |
| US7820145B2 (en) * | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US8486374B2 (en) * | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
| US20050123576A1 (en) * | 2003-12-03 | 2005-06-09 | Ilana Lavon | Mupirocin compositions for topical use, an improved process of making same and methods of using same |
| KR20070080823A (ko) * | 2007-01-31 | 2007-08-13 | 주식회사 티디에스팜 | 활성약물 함유 상처 치료용 하이드로겔 제제 |
-
2010
- 2010-10-20 EP EP10382274A patent/EP2444067A1/en not_active Withdrawn
-
2011
- 2011-10-19 CN CN201180050316.6A patent/CN103189048B/zh active Active
- 2011-10-19 MX MX2013004394A patent/MX2013004394A/es active IP Right Grant
- 2011-10-19 EP EP11770791.9A patent/EP2629756B1/en active Active
- 2011-10-19 ES ES11770791.9T patent/ES2531846T3/es active Active
- 2011-10-19 WO PCT/EP2011/068242 patent/WO2012052472A1/en not_active Ceased
- 2011-10-19 JP JP2013534305A patent/JP5954745B2/ja active Active
- 2011-10-19 KR KR1020137011960A patent/KR101776362B1/ko active Active
- 2011-10-19 PT PT117707919T patent/PT2629756E/pt unknown
- 2011-10-19 US US13/879,008 patent/US9205149B2/en active Active
- 2011-10-19 BR BR112013009371A patent/BR112013009371B1/pt active IP Right Grant
- 2011-10-19 CA CA2814103A patent/CA2814103C/en active Active
- 2011-10-19 RU RU2013122845/15A patent/RU2563840C2/ru active
- 2011-10-19 NZ NZ609655A patent/NZ609655A/en unknown
- 2011-10-19 AU AU2011317636A patent/AU2011317636B2/en active Active
- 2011-10-19 PL PL11770791T patent/PL2629756T3/pl unknown
-
2013
- 2013-04-09 ZA ZA2013/02560A patent/ZA201302560B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011317636A1 (en) | 2013-05-23 |
| AU2011317636B2 (en) | 2016-05-12 |
| NZ609655A (en) | 2014-08-29 |
| KR20130124504A (ko) | 2013-11-14 |
| RU2013122845A (ru) | 2014-11-27 |
| PL2629756T3 (pl) | 2015-06-30 |
| RU2563840C2 (ru) | 2015-09-20 |
| ZA201302560B (en) | 2014-06-25 |
| CN103189048B (zh) | 2014-11-26 |
| KR101776362B1 (ko) | 2017-09-07 |
| CA2814103A1 (en) | 2012-04-26 |
| JP2013543518A (ja) | 2013-12-05 |
| EP2629756A1 (en) | 2013-08-28 |
| CA2814103C (en) | 2018-06-12 |
| CN103189048A (zh) | 2013-07-03 |
| BR112013009371A2 (pt) | 2016-07-26 |
| US9205149B2 (en) | 2015-12-08 |
| JP5954745B2 (ja) | 2016-07-20 |
| PT2629756E (pt) | 2015-05-21 |
| US20130267587A1 (en) | 2013-10-10 |
| EP2629756B1 (en) | 2014-12-24 |
| BR112013009371B1 (pt) | 2019-08-27 |
| EP2444067A1 (en) | 2012-04-25 |
| MX2013004394A (es) | 2013-08-21 |
| WO2012052472A1 (en) | 2012-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2531846T3 (es) | Composición farmacéutica tópica de mupirocina | |
| Panwar et al. | Emulgel: A review | |
| ES2391914T3 (es) | Formulación farmacéutica tópica | |
| ES2985068T3 (es) | Composición tópica que comprende tacrolimus | |
| EA011244B1 (ru) | Новые композиции для местной доставки | |
| ES2860578T3 (es) | Composición para su uso en la reducción de la formación de costras y la promoción de la cicatrización. | |
| ES2651639T3 (es) | Formulaciones tópicas de tipo suspensión que comprenden depsipéptido cíclico | |
| US10028927B2 (en) | Topical pharmaceutical formulation | |
| ES2582635T3 (es) | Utilización de excipientes como conservantes y composiciones farmacéuticas que los contienen | |
| EP2590620B1 (en) | Stable aqueous formulations comprising poorly water soluble active ingredients | |
| ES2625112T3 (es) | Loción en emulsión de tipo aceite en agua que contiene 22-oxa-1 alfa,25-dihidroxivitamina D3 y método de tratamiento de una enfermedad cutánea utilizando la misma | |
| ES2608794T3 (es) | Composiciones de gel | |
| JP2024507011A (ja) | エマルション組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および／または処置におけるその使用 | |
| US11376213B2 (en) | Topical pharmaceutical formulation | |
| Verma et al. | Emulgel: a recent technique for topical drug delivery-a review | |
| Parmar et al. | FORMULATION AND EVALUATION STUDIES OF VALACYCLOVIR TOPICAL GEL FOR ANTIVIRAL ACTIVITY | |
| Mirgorod et al. | Grounds for selection of bases for preparing gel with phytos complex for treatment of skin diseases | |
| RU2498806C2 (ru) | Фармацевтический состав для лечения инфекционных воспалительных заболеваний в гинекологии и способ его получения | |
| ES2316308B1 (es) | Medicamento a base de metronidazol y acido azelaico para el tratamiento por via topica de la enfermedad rosacea de mejor asimilacion, y procedimiento de preparacion. | |
| CN120981221A (zh) | 用于局部施用的组合物 | |
| Augustine | Formulation and evaluation of topical semisolids containing aceclofenac | |
| Verma et al. | Asian Journal of Phytomedicine and Clinical Research | |
| Patel | Preparation and Evaluation of Topical Preparation of Norfloxacin |